Co-Authors
This is a "connection" page, showing publications co-authored by DIANE C BODURKA and KAREN H LU.
Connection Strength
1.709
-
Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2005 Jan; 105(1):217-8; author reply 218-9.
Score: 0.262
-
Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
Score: 0.137
-
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
Score: 0.106
-
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol. 2011 May 01; 121(2):358-63.
Score: 0.100
-
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
Score: 0.099
-
Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011 Feb; 120(2):229-32.
Score: 0.099
-
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
Score: 0.074
-
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
Score: 0.073
-
Are women ready for the HPV vaccine? Gynecol Oncol. 2006 Oct; 103(1):151-4.
Score: 0.071
-
Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
Score: 0.064
-
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol. 2003 Mar; 88(3):363-8.
Score: 0.058
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.048
-
Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019 03; 152(3):514-521.
Score: 0.044
-
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
Score: 0.040
-
Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
Score: 0.039
-
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
Score: 0.038
-
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
Score: 0.034
-
Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55.
Score: 0.031
-
Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
Score: 0.030
-
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
Score: 0.029
-
Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72.
Score: 0.024
-
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
Score: 0.022
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.022
-
Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009 Mar; 200(3):288.e1-8.
Score: 0.022
-
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71.
Score: 0.021
-
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008 Apr 14; 8:101.
Score: 0.021
-
Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007 Oct; 26(4):404-9.
Score: 0.020
-
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
Score: 0.019
-
Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005 Dec; 90(12):1725-6.
Score: 0.017
-
Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004 Apr; 28(4):496-504.
Score: 0.016
-
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
Score: 0.015
-
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol. 2002 Jan; 99(1):3-10.
Score: 0.013